Please wait while the formulary information is being retrieved.
BENLYSTA (BELIMUMAB)
- Systemic lupus erythematosus
- Benlysta Subcutaneous Syringe
- Benlysta Subcutaneous Auto-injector
- Benlysta Intravenous Solution
- By Indication
200 mg/mL subcutaneous syringe
- Inject 1 milliliter (200 mg) by subcutaneous route once weekly on thesame day of each week in the abdomen or thigh; rotate injection sites
200 mg/mL subcutaneous auto-injector
- Inject 1 milliliter (200 mg) by subcutaneous route once weekly on thesame day of each week in the abdomen or thigh; rotate injection sites
120 mg intravenous solution
- Infuse 10 mg/kg over 60 minute(s) by intravenous route every 4 weeks
400 mg intravenous solution
- Infuse 10 mg/kg over 60 minute(s) by intravenous route every 4 weeks
Systemic lupus erythematosus
- Infuse 10 mg/kg over 60 minute(s) by intravenous route every 4 weeks
- Inject 1 milliliter (200 mg) by subcutaneous route once weekly on thesame day of each week in the abdomen or thigh; rotate injection sites
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Progressive multifocal leukoencephalopathy
- Severe infection
- Suicidal ideation
Severe
Moderate
- Depression
- Malignancy
BENLYSTA (BELIMUMAB)
- Systemic lupus erythematosus
- Infection
- Bronchitis
- Diarrhea
- Fever
- Influenza
- Injection site sequelae
- Insomnia
- Limb pain
- Migraine
- Nausea
- Pharyngitis
- Sinusitis
- Upper respiratory infection
- Urinary tract infection
More Frequent
Severe
Less Severe
- Cellulitis
- Leukopenia
- Pneumonia
- Cystitis
- Depression
- Fatigue
- Mood changes
- Pruritus of skin
- Skin rash
- Symptoms of anxiety
- Urticaria
- Viral gastroenteritis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Angioedema
- Dyspnea
- Hematoma
- Hypoxia
- Malignancy
- Progressive multifocal leukoencephalopathy
- Suicidal
- Suicidal ideation
Less Severe
- Bradycardia
- Headache disorder
- Hypotension
- Myalgias
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Belimumab (IV)
Safety and efficacy not established in age < 5 years.
Safety and efficacy of subcutaneous administration not established. Intravenous belimumab is indicated in children aged 5 years and older.
- 1 Day – 5 Years
- Safety and efficacy not established in age < 5 years.
- 1 Day – 18 Years
- Safety and efficacy not established in age < 5 years.
Belimumab (subcutaneous)
Safety and efficacy not established in age < 5 years.
Safety and efficacy of subcutaneous administration not established. Intravenous belimumab is indicated in children aged 5 years and older.
- 1 Day – 5 Years
- Safety and efficacy of subcutaneous administration not established. Intravenous belimumab is indicated in children aged 5 years and older.
- 1 Day – 18 Years
- Safety and efficacy of subcutaneous administration not established. Intravenous belimumab is indicated in children aged 5 years and older.
Belimumab
- Severity Level:
2
- Additional Notes: Insufficient human data available; crosses placenta
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Belimumab
Insufficient data available; immunoglobulins excreted
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available; immunoglobulins excreted |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Systemic lupus erythematosus | |
| M32 | Systemic lupus erythematosus (SLe) |
| M32.0 | Drug-induced systemic lupus erythematosus |
| M32.1 | Systemic lupus erythematosus with organ or system involvement |
| M32.10 | Systemic lupus erythematosus, organ or system involvement unspecified |
| M32.11 | Endocarditis in systemic lupus erythematosus |
| M32.12 | Pericarditis in systemic lupus erythematosus |
| M32.13 | Lung involvement in systemic lupus erythematosus |
| M32.14 | Glomerular disease in systemic lupus erythematosus |
| M32.15 | Tubulo-interstitial nephropathy in systemic lupus erythematosus |
| M32.19 | Other organ or system involvement in systemic lupus erythematosus |
| M32.8 | Other forms of systemic lupus erythematosus |
| M32.9 | Systemic lupus erythematosus, unspecified |
| 0-9 | A-Z |
|---|---|
| M32 | Systemic lupus erythematosus (SLe) |
| M32.0 | Drug-induced systemic lupus erythematosus |
| M32.1 | Systemic lupus erythematosus with organ or system involvement |
| M32.10 | Systemic lupus erythematosus, organ or system involvement unspecified |
| M32.11 | Endocarditis in systemic lupus erythematosus |
| M32.12 | Pericarditis in systemic lupus erythematosus |
| M32.13 | Lung involvement in systemic lupus erythematosus |
| M32.14 | Glomerular disease in systemic lupus erythematosus |
| M32.15 | Tubulo-interstitial nephropathy in systemic lupus erythematosus |
| M32.19 | Other organ or system involvement in systemic lupus erythematosus |
| M32.8 | Other forms of systemic lupus erythematosus |
| M32.9 | Systemic lupus erythematosus, unspecified |
Formulary Reference Tool